Biomarker testing for patients with advanced non–small cell lung cancer: real-world issues and tough choices
NA Pennell, ME Arcila, DR Gandara… - American Society of …, 2019 - ascopubs.org
Over the last decade, the treatment of patients with advanced non–small cell lung cancer
(NSCLC) has become reliant on tissue and/or blood biomarkers to help guide treatment …
(NSCLC) has become reliant on tissue and/or blood biomarkers to help guide treatment …
[HTML][HTML] Multilevel opportunities to address lung cancer stigma across the cancer control continuum
HA Hamann, ES Ver Hoeve, L Carter-Harris… - Journal of Thoracic …, 2018 - Elsevier
The public health imperative to reduce the burden of lung cancer has seen unprecedented
progress in recent years. Fully realizing the advances in lung cancer treatment and control …
progress in recent years. Fully realizing the advances in lung cancer treatment and control …
[HTML][HTML] Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors
CA Milbury, J Creeden, WK Yip, DL Smith, V Pattani… - PLoS …, 2022 - journals.plos.org
FoundationOne® CDx (F1CDx) is a United States (US) Food and Drug Administration (FDA)-
approved companion diagnostic test to identify patients who may benefit from treatment in …
approved companion diagnostic test to identify patients who may benefit from treatment in …
Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non–small cell lung cancer
Purpose: Complete and timely tissue genotyping is challenging, leading to significant
numbers of patients with newly diagnosed metastatic non–small cell lung cancer (mNSCLC) …
numbers of patients with newly diagnosed metastatic non–small cell lung cancer (mNSCLC) …
[HTML][HTML] Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C …
S Peters, R Dziadziuszko, A Morabito, E Felip… - Nature medicine, 2022 - nature.com
Tumor mutational burden (TMB) is being explored as a predictive biomarker for cancer
immunotherapy outcomes in non-small cell lung cancer. BFAST (NCT03178552)—an open …
immunotherapy outcomes in non-small cell lung cancer. BFAST (NCT03178552)—an open …
Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue-and plasma-based methodologies
JI Odegaard, JJ Vincent, S Mortimer, JV Vowles… - Clinical Cancer …, 2018 - AACR
Purpose: To analytically and clinically validate a circulating cell-free tumor DNA sequencing
test for comprehensive tumor genotyping and demonstrate its clinical feasibility …
test for comprehensive tumor genotyping and demonstrate its clinical feasibility …
[HTML][HTML] Electromagnetic navigation bronchoscopy for peripheral pulmonary lesions: one-year results of the prospective, multicenter NAVIGATE study
EE Folch, MA Pritchett, MA Nead, MR Bowling… - Journal of Thoracic …, 2019 - Elsevier
Introduction Electromagnetic navigation bronchoscopy (ENB) is a minimally invasive
technology that guides endoscopic tools to pulmonary lesions. ENB has been evaluated …
technology that guides endoscopic tools to pulmonary lesions. ENB has been evaluated …
[HTML][HTML] The International Association for the Study of Lung Cancer global survey on molecular testing in lung cancer
MP Smeltzer, MW Wynes, S Lantuejoul, R Soo… - Journal of Thoracic …, 2020 - Elsevier
Introduction Access to targeted therapies for lung cancer depends on the accurate
identification of patients' biomarkers through molecular testing. The International Association …
identification of patients' biomarkers through molecular testing. The International Association …
Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non–small-cell lung cancer using a decision …
NA Pennell, A Mutebi, ZY Zhou, ML Ricculli… - JCO Precision …, 2019 - ascopubs.org
PURPOSE The aim of the current study was to assess the economic impact of using next-
generation sequencing (NGS) versus single-gene testing strategies among patients with …
generation sequencing (NGS) versus single-gene testing strategies among patients with …
A blood-based assay for assessment of tumor mutational burden in first-line metastatic NSCLC treatment: results from the MYSTIC study
Purpose: Tumor mutational burden (TMB) has been shown to be predictive of survival
benefit in patients with non–small cell lung cancer (NSCLC) treated with immune checkpoint …
benefit in patients with non–small cell lung cancer (NSCLC) treated with immune checkpoint …